152 related articles for article (PubMed ID: 38241844)
1. Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy.
Yildirim D; Kardas RC; Gun M; Kaya B; Vasi I; Duran R; Karadeniz H; Avanoglu Guler A; Kucuk H; Erden A; Goker B; Ozturk MA; Tufan A
Int Immunopharmacol; 2024 Feb; 128():111491. PubMed ID: 38241844
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
[TBL] [Abstract][Full Text] [Related]
4. Work productivity impairment in patients with familial Mediterranean fever and effects of interleukin-1 antagonists.
Suticen E; Atas N; Guler AA; Akdogan O; Babaoğlu H; Satis H; Karadeniz H; Haznedaroglu S; Ozturk MA; Tufan A
Clin Rheumatol; 2021 Jul; 40(7):2865-2871. PubMed ID: 33527168
[TBL] [Abstract][Full Text] [Related]
5. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
Hentgen V; Vinit C; Fayand A; Georgin-Lavialle S
Front Immunol; 2020; 11():971. PubMed ID: 32670263
[No Abstract] [Full Text] [Related]
6. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial.
Koga T; Sato S; Miyamoto J; Hagimori N; Kawazoe Y; Arinaga K; Fukushima C; Yamamoto H; Kawakami A
Trials; 2018 Dec; 19(1):715. PubMed ID: 30594222
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
Babaoglu H; Varan O; Kucuk H; Atas N; Satis H; Salman R; Ozturk MA; Goker B; Tufan A; Haznedaroglu S
J Clin Rheumatol; 2020 Jan; 26(1):7-13. PubMed ID: 30048391
[TBL] [Abstract][Full Text] [Related]
8. Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).
El Hasbani G; Jawad A; Uthman I
Orphanet J Rare Dis; 2019 Oct; 14(1):224. PubMed ID: 31615541
[TBL] [Abstract][Full Text] [Related]
9. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
Karabulut Y; Gezer HH; Duruöz MT
Rheumatol Int; 2022 Jan; 42(1):81-86. PubMed ID: 34550430
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
11. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
[TBL] [Abstract][Full Text] [Related]
12. Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents.
Eroglu FK; Beşbaş N; Topaloglu R; Ozen S
Rheumatol Int; 2015 Oct; 35(10):1733-7. PubMed ID: 26001859
[TBL] [Abstract][Full Text] [Related]
13. Biologic therapy in familial Mediterranean fever.
Koga T; Migita K; Kawakami A
Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
[TBL] [Abstract][Full Text] [Related]
14. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M
Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
[TBL] [Abstract][Full Text] [Related]
15. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.
Eren Akarcan S; Dogantan S; Edeer Karaca N; Aksu G; Kutukculer N
Rheumatol Int; 2020 Jan; 40(1):161-168. PubMed ID: 31273456
[TBL] [Abstract][Full Text] [Related]
16. Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience.
Konte EK; Haslak F; Yildiz M; Gucuyener N; Ulkersoy I; Gunalp A; Aslan E; Adrovic A; Sahin S; Barut K; Kasapcopur O
Eur J Pediatr; 2023 Dec; 182(12):5473-5482. PubMed ID: 37777601
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
[TBL] [Abstract][Full Text] [Related]
18. [INTERLEUKIN 1 INHIBITORS--A NEW HORIZON IN THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER].
Shouval R; Livneh A; Ben-Zvi I
Harefuah; 2015 Nov; 154(11):716-9, 741. PubMed ID: 26821505
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment. Retrospective analysis.
Sargin G; Kose R; Senturk T
Sao Paulo Med J; 2019 May; 137(1):39-44. PubMed ID: 31116269
[TBL] [Abstract][Full Text] [Related]
20. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
Gül A
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]